# Mounjaro eligibility in the UK: the criteria for men Canonical URL: https://www.hemed.com/blog/mounjaro-eligibility-men-uk Plain-text URL: https://www.hemed.com/blog/mounjaro-eligibility-men-uk/llms.txt Published: 2026-11-12 Modified: 2026-11-12 Author: The HeMed clinical team Topic: Weight-loss treatment Topic URL: https://www.hemed.com/blog/topic/weight-loss-treatment Tags: Mounjaro, Eligibility and choosing a programme Reading time: 23 min Publisher: HeMed (https://www.hemed.com/) ## Summary The UK licence criteria for Mounjaro are the same for men and women. The BMI thresholds, how cholesterol and blood sugar count, and who decides. ## Article You may be eligible for Mounjaro (tirzepatide) if you are an adult with a BMI (body mass index) of 30 or more. You may also be eligible with a BMI of 27 to under 30 and at least one weight-related health condition. The criteria are written without reference to sex: they are the same for men and women. Raised cholesterol and raised blood sugar count through a condition, not through a number. The licence sets no cholesterol figure and no blood sugar figure for eligibility. Whether you are prescribed it is a clinical decision. A prescriber checks your health and your medical history first. BMI is your weight in kilograms divided by your height in metres squared. Mounjaro contains tirzepatide. The medicines regulator says medicines of this type mimic a natural hormone released after eating. It says Mounjaro also acts on a second hormone involved in appetite and blood sugar control. The licence is a medicine’s UK approval. Its rules sit in the Summary of Product Characteristics (SmPC), the document the regulator approves. The regulator is the Medicines and Healthcare products Regulatory Agency (MHRA). ### What does the UK licence say about who Mounjaro is for? The licence covers adults with an initial BMI of 30 or more, a band it calls obesity. It also covers adults with an initial BMI of 27 to under 30 who have at least one weight-related comorbid condition. The licence calls that band overweight. A comorbid condition is a health condition that exists alongside excess weight. “Initial” means your BMI when treatment starts. The licensed use is weight management, including weight loss and weight maintenance. It is an adjunct to a reduced-calorie diet and increased physical activity. An adjunct is an addition: diet and activity are part of the licensed use, not an optional extra. #### What does each BMI band require? The UK licence criteria for adults starting Mounjaro for weight management (SmPC section 4.1, text revised 29 August 2026). Whether treatment is right for a person is a clinical decision. Your BMI when treatment starts | What the licence requires 30 or more | No other condition is required. The licence calls this band obesity. 27 to under 30 | At least one weight-related comorbid condition. The licence calls this band overweight. Under 27 | Outside the licensed criteria for starting treatment. The MHRA says it has not assessed the safety and effectiveness of these medicines outside their licensed use. The licence for weight management is for adults. Safety and efficacy have not been established under 18 for this use. The MHRA adds that these medicines are not for people who want to lose weight for aesthetic or cosmetic purposes. The licence also covers type 2 diabetes, with its own criteria. This article covers the adult weight-management criteria only. ### Do raised cholesterol and blood sugar count towards eligibility? They can, through a condition rather than a number. In the 27 to under 30 band the licence asks for at least one weight-related comorbid condition. It names six examples. - Hypertension (high blood pressure). - Dyslipidaemia (abnormal levels of fats in the blood). - Obstructive sleep apnoea (breathing problems during sleep). - Cardiovascular disease (a history of heart attack, stroke or blood vessel problems). - Prediabetes (blood sugar higher than normal, below the range for diabetes). - Type 2 diabetes. The other words in brackets are the patient leaflet’s own. The MHRA’s announcement of the licence gave prediabetes, high blood pressure, high cholesterol or heart problems as examples. NICE notes that the list is not exhaustive. NICE is the National Institute for Health and Care Excellence, which advises the NHS on care. At a BMI of 30 or more the licence requires no other condition. #### Is there a cholesterol or blood sugar number for eligibility? No. The licence sets no cholesterol value and no blood sugar value for eligibility. NICE’s recommendation for the NHS names none either. In the 27 to under 30 band the condition counts, not a reading. How three UK documents treat cholesterol and blood sugar for Mounjaro eligibility, as they stood on 12 November 2026. Whether treatment is right for a person is a clinical decision. Document | Cholesterol | Blood sugar The UK licence (SmPC section 4.1) | Names dyslipidaemia as an example condition in the 27 to under 30 band. Sets no figure. | Names prediabetes and type 2 diabetes as example conditions in that band. Sets no figure. NICE TA1026, the NHS recommendation | Asks for at least 1 weight-related comorbidity. Sets no figure. | Asks for at least 1 weight-related comorbidity. Sets no figure. NHS England, the phased rollout in primary care (for example, GP practices) | Defines dyslipidaemia with blood-fat figures, set out below. | Counts established type 2 diabetes. Prediabetes is not one of its five conditions. #### What counts as raised blood sugar? Prediabetes means your blood sugar is higher than normal but not high enough for a diabetes diagnosis. NICE uses the term non-diabetic hyperglycaemia for the same thing. NICE’s definition includes an HbA1c of 42 to 47 mmol/mol. HbA1c is your average blood sugar over roughly the past three months. For possible type 2 diabetes without symptoms, NICE gives an HbA1c of 48 mmol/mol or above and asks for a second blood test. These figures define the conditions. They are not eligibility thresholds for the medicine. Our article on prediabetes in men explains the range. #### What counts as raised cholesterol? The NHS guide to healthy levels gives total cholesterol below 5 mmol/L. It gives non-HDL cholesterol below 4 mmol/L and labels it bad cholesterol. For men it gives HDL cholesterol above 1.0 mmol/L and labels it good cholesterol. The NHS says those levels are a guide for healthy adults. A good target for you depends on your age, your health conditions and your risk of cardiovascular disease. The guide is not an eligibility threshold for the medicine. One NHS document does attach figures to dyslipidaemia. NHS England uses them to define the condition for its phased primary care rollout, not for the licence. Under that definition, dyslipidaemia means any one of the following. - Treatment with lipid-lowering therapy (medicines that lower blood fats). - LDL cholesterol of 4.1 mmol/L or more. - HDL cholesterol under 1.0 mmol/L for men. - Triglycerides of 1.7 mmol/L or more, fasting where possible. LDL cholesterol and triglycerides are blood fats. These figures belong to the NHS rollout. They are not in the licence. #### Does the condition need to be diagnosed? The licence does not say how a condition is established. SURMOUNT-1 is one of the trials behind the licence. There, a qualifying condition in the 27 to under 30 band meant a previous diagnosis. NHS England’s definitions for high blood pressure, sleep apnoea, cardiovascular disease and type 2 diabetes are established diagnoses too. The pharmacy regulator expects a prescriber to verify the medical history behind a condition independently, because these are often long-term conditions. Our guide to what a clinician checks first when cholesterol or blood sugar is raised covers the next steps. ### Can you check at home whether you meet the criteria? You can check your BMI and your existing diagnoses yourself. You cannot confirm eligibility on your own: a prescriber decides after checking your health and your history. What you can check at home: - Your BMI. The NHS calculator needs your height and your weight. - Your waist. If your BMI is under 35, the NHS suggests checking your waist to height ratio. Try to keep your waist to less than half your height. It is not a licence criterion. - Your diagnoses and medicines. List the conditions you have been diagnosed with and every medicine you take. A prescriber takes both as part of a full medical history. - Your blood pressure. A reading of 135/85 or higher at home is usually considered high. Under NHS England’s definition, the qualifying condition is an established diagnosis that needs treatment. #### What can a home check not tell you? Three things need a blood test. - Your cholesterol. High cholesterol does not usually cause symptoms, and only a blood test finds it. - Prediabetes, which is diagnosed by a blood test. - Type 2 diabetes, which is also diagnosed with a blood test. In SURMOUNT-1 the qualifying condition was a previous diagnosis. A home check does not settle eligibility. The NHS says its BMI tool should not be used to diagnose any symptoms. For an online prescription, the weight and height you report must be verified independently. ### Who should not take Mounjaro? The UK licence has one contraindication: hypersensitivity (an allergy) to tirzepatide or any of the other ingredients. A contraindication is a situation in which a medicine must not be used. Everything else a prescriber weighs is a warning or precaution rather than an automatic no. The NHS says most adults can use tirzepatide. It also says you will usually only be prescribed it for weight loss if your BMI meets the eligibility criteria. The NHS adds that it may not be suitable after an allergic reaction to it or to another medicine of its type. The same applies with current or past acute pancreatitis. #### What are the warnings a prescriber checks? The SmPC’s special warnings and precautions, in plain words. Each is a caution the prescriber weighs. - A history of pancreatitis (inflammation of the pancreas). Tirzepatide has not been studied in people with this history and should be used with caution. If pancreatitis is suspected during treatment, the medicine is stopped. If it is confirmed, it is not restarted. Persistent, severe abdominal pain needs immediate medical attention. - Severe gastrointestinal disease, including severe gastroparesis (delayed stomach emptying). Not studied, so used with caution. - Diabetes medicines. With insulin or a sulfonylurea (another diabetes medicine) the risk of low blood sugar may rise. Those doses may be reduced. - Diabetic retinopathy (diabetic eye disease). A rapid improvement in blood sugar control has been associated with a temporary worsening. People with this condition should be monitored closely. - Dehydration and the kidneys. Nausea, vomiting and diarrhoea may lead to dehydration. Dehydration could worsen kidney function. Experience in severe kidney or liver impairment is limited, so caution is advised. #### What about surgery and older age? Two further points the SmPC raises. - Surgery under general anaesthesia or deep sedation. The licence says the risk of food or drink remaining in the stomach should be considered before such procedures. Tell your healthcare team and the anaesthetist that you take Mounjaro. The MHRA says to continue as prescribed and not to stop without first discussing it with your doctor. - Limited data. Only very limited data are available in people aged 85 or more. #### Is there a thyroid cancer warning in the UK? No. The UK SmPC and the patient leaflet carry no thyroid contraindication or warning. The thyroid wording sits in the preclinical section (animal and laboratory studies). It describes tumours in thyroid C-cells (one of the thyroid’s cell types) in a 2-year study in rats. It says the human relevance of these findings is unknown. A 6-month study in mice showed no increase. If you have read about a thyroid warning elsewhere, check the UK leaflet. It is the document that applies to a UK prescription. #### Which other medicines matter? Tirzepatide delays stomach emptying and can affect how quickly oral medicines are absorbed. For most oral medicines, no dose adjustment is expected. The licence recommends monitoring for oral medicines where the dose needs to be precise, such as warfarin and digoxin. The monitoring applies especially at the start and after a dose increase. Tell the prescriber every medicine you take. Getting all the information needed to check that a supply is safe and appropriate is part of what they must do. ### What must a prescriber check before prescribing Mounjaro online? In Great Britain, the pharmacy regulator says medicines used for weight management are not suitable to be prescribed by a questionnaire model alone. The regulator is the General Pharmaceutical Council (GPhC). Its February 2025 guidance sets the safeguards an online prescriber must have in place. They cover identity, weight and height, medical history and your GP. The MHRA adds that a consultation with a healthcare professional must happen before a private prescription can be issued. #### What are the safeguards? - Identity. Processes to check who you are, so the medicine goes to the right person. - Not a questionnaire alone. The prescriber independently verifies what you provide, for example through timely two-way communication, your clinical records or contact with your GP or another provider. - Weight, height and BMI. Verified by a different route from what you typed in. The routes include a video consultation, an in-person check, your clinical records or another healthcare provider such as your GP. - Medical history. Where a long-term condition underpins eligibility, the history behind it is verified independently. - Your GP. Your GP’s contact details and your consent to share information about the prescription. If you have no GP or do not consent, the prescriber decides whether it is safe to prescribe. - UK guidance. Prescribing within national prescribing guidelines for the UK. If the prescriber cannot verify the information, you should be directed to an appropriate care provider for assessment. Doctors who prescribe follow the General Medical Council’s guidance, which the GPhC document also cites. #### Can weight be verified by phone or photograph? No. A phone call is not an appropriate way to verify weight for a weight-management medicine. A photograph or pre-recorded video alone is not appropriate either, because weight is hard to verify that way and an image can be edited. The GPhC says that is particularly so at a BMI of 25 to 30. #### What did the regulator find in 2026? The GPhC reviewed inspections and concerns from January 2024 to December 2025 and published its findings in April 2026. It had received 1,307 concerns about weight management medicines and services. Prescribing practice (unsafe or inappropriate prescribing and poor clinical oversight) accounted for 27% of them. The review recorded public concerns about instances where BMI could be self-declared through online questionnaires alone, or supported by photographs that could be easily manipulated. It told prescribers to verify medical history, weight and height rather than rely on self-reported questionnaires. For you, the practical test is simple. Ask any provider how they verify your weight and your history, and what they measure before they prescribe. ### Is a blood test required before starting? The licence does not require one. It names no blood test before starting. NICE’s prescribing guide lists blood tests among the assessments that depend on clinical circumstances. The guide asks for height, weight and BMI. It also asks for a full medical history. It then asks for any other assessments indicated, to check current conditions and to identify unknown ones. Those may include the following. - Blood pressure. - A lipid profile (cholesterol and other blood fats). - HbA1c and blood glucose. - Kidney and liver function tests. - A full blood count and thyroid function tests. NICE says not all of these will be needed, and that recent results can be used if they are available. The guide supports NICE guidance and is not itself guidance. With insulin or a sulfonylurea, the licence says blood glucose self-monitoring is necessary to adjust those doses. #### Why might a prescriber ask for one? A blood test is one way a prescriber can check a qualifying condition rather than take it on trust. The GPhC lists a need for a diagnostic test before prescribing among the factors in choosing how to consult. NICE’s guideline says to identify any comorbidities after the initial assessment, and to start managing them as soon as they are identified. Our guide to the markers a blood test checks covers cholesterol, liver enzymes, HbA1c and thyroid function. It does not cover kidney function or a full blood count. ### Is eligibility different for men? No. The licence criteria and NICE’s NHS recommendation are written without reference to sex. The sex-specific wording in the licence concerns pregnancy, breastfeeding and oral contraception. No dose adjustment is needed based on gender. The SmPC states that a reduction in body weight was observed irrespective of the following. - Age - Sex - Race and ethnicity - Baseline BMI - Glycaemic status (blood sugar status) Average trial results are not a prediction of individual results. #### How many men were in SURMOUNT-1? Men were a minority in SURMOUNT-1. It is one of the weight-management trials described in the SmPC. It randomised 2,539 adults, meaning it assigned them by chance to tirzepatide or a placebo (a matching treatment with no active medicine). The SmPC records that 67.5% of participants were women. The posted trial record counts 825 men and 1,714 women: about 32.5% men. Neither document publishes a result for men alone. People with type 2 diabetes were excluded from SURMOUNT-1, and 40.6% of participants had prediabetes at the start. #### What if muscle pushes my BMI up? The licence uses BMI, so a prescriber starts there. NICE says to interpret BMI with caution in adults with high muscle mass. The NHS says its calculator cannot tell the difference between muscle and fat. Below a BMI of 35, NICE uses waist-to-height ratio alongside BMI as a practical estimate of fat carried around the middle. These measures inform the clinical picture. They do not replace the BMI criterion in the licence. #### Do the cholesterol figures differ for men? One of them does. The NHS guide to healthy levels and NHS England’s definition both give men a lower HDL figure than women. The NHS also says men are more likely to get high cholesterol. ### Is Mounjaro prescribed on the NHS for men? Yes, within narrower criteria than the licence. NICE recommends tirzepatide on the NHS for adults with an initial BMI of at least 35 and at least 1 weight-related comorbidity. It can be prescribed in primary care or in specialist weight management services. Access is phased, starting with the highest clinical need. The company proposed a wider group: a BMI of at least 30 with a comorbidity. NICE did not recommend that group, because its cost-effectiveness estimates were above the range NICE accepts. #### How do the NHS criteria compare with the licence? UK eligibility for Mounjaro by route (the licence against the NHS criteria) as the cited documents stood on 12 November 2026. Whether treatment is right for a person is a clinical decision. Route | BMI and conditions | Setting and limits The UK licence. The GPhC expects an online prescriber to work within national prescribing guidelines for the UK. | Initial BMI of 30 or more; or 27 to under 30 with at least one weight-related comorbid condition. | A clinician’s assessment. A decision on continuing is required if less than 5% of initial weight is lost 6 months after reaching the highest tolerated dose. NICE TA1026, the NHS recommendation (2024). | Initial BMI of at least 35 and at least 1 weight-related comorbidity. | Primary care or a specialist weight management service. The same decision point at 6 months on the highest tolerated dose. NHS England, primary care, year 1 (2025/26). | 4 or more of five qualifying conditions and a BMI of 40 or more. | Funded in primary care from 23 June 2025. NHS England, primary care, year 2 (2026/27). | 4 or more of the five and a BMI of 35 to 39.9. | NICE dates this group from around June 2026. NHS England, primary care, year 3 (2027/28 and 2028/29). | 3 of the five and a BMI of 40 or more. | NICE dates this group from around March 2027. #### Which conditions count on the NHS? The five qualifying conditions are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Prediabetes is on the licence’s list of examples but is not one of the five. Each year’s group is added to the earlier ones. Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. The reduction is usually 2.5. #### How is it prescribed on the NHS? NHS access is phased. NICE says that for the first 3 years not everyone will be able to have tirzepatide. It starts with people with the highest clinical need. In specialist weight management services, funding for tirzepatide has applied since 24 March 2025 for anyone who meets the NICE criteria. A prescribing clinician must approve treatment. In primary care, funding began on 23 June 2025 for the groups in the table. NHS England’s leaflet says your GP can prescribe it if the national guidelines apply to you. NHS England tells people to check their eligibility with their local integrated care board, the NHS body that plans local services. Support with diet and behaviour change is a mandatory part of NHS treatment. NHS England sets no maximum treatment period. Our article on GP or online clinician-led weight management works through the decision. Our wider guide to eligibility covers both routes. The Wegovy eligibility criteria are set out in their own article. ### How does HeMed fit in? Always a clinical decision, made after your blood test and health review. Adults with a BMI of 30 or over, or 27 or over alongside a weight-related health condition, may be considered. Treatment is not suitable in pregnancy or when trying to conceive, under 18, or with certain medical histories. The clinician screens for these. The patient information leaflet carries the full list. If your blood test shows the plan isn’t suitable for you, we explain why and refund your first payment in full. HeMed starts with a blood test. We measure 10 metabolic markers across four systems from a needle-free blood test at home. A clinician reviews your blood test first. If you’ve been on treatment within the last 2 months, the baseline test is your choice. Your clinician can assess you from proof of your prescription and your medical history. Mounjaro is a prescription medicine for weight management. Whether it’s right for you is a clinical decision, made from your health information and your baseline blood test. The Care Quality Commission (CQC) is the regulator of health and social care services in England. Clinical, consultation and prescribing services are provided by eMed, a CQC-registered provider. ### Frequently asked questions **What BMI do you need for Mounjaro in the UK?** Under the UK licence: an initial BMI of 30 or more, or 27 to under 30 with at least one weight-related comorbid condition. On the NHS, NICE asks for a BMI of at least 35 and at least 1 weight-related comorbidity. Access is phased, starting with the highest clinical need. A BMI figure is where the assessment starts, not where it ends. A prescriber checks your history, your other conditions and the medicines you take before deciding. **Is there a cholesterol level that makes you eligible for Mounjaro?** No. The licence names dyslipidaemia as an example condition in the 27 to under 30 band and sets no cholesterol figure. NICE’s NHS recommendation sets none either. NHS England defines dyslipidaemia with blood-fat figures for its phased primary care rollout only. A prescriber is expected to verify the history behind a condition rather than take it from a form. **Does prediabetes count towards Mounjaro eligibility?** Under the licence, prediabetes is one of the six example conditions in the 27 to under 30 band. NICE calls it non-diabetic hyperglycaemia. Its definition includes an HbA1c of 42 to 47 mmol/mol. On the NHS primary care rollout it does not count: the five qualifying conditions do not include it. Prediabetes is diagnosed by a blood test. **Can I check at home whether I meet the criteria for Mounjaro?** You can work out your BMI and list your diagnosed conditions and your medicines. You cannot know whether you have raised cholesterol, prediabetes or type 2 diabetes without a blood test. Eligibility is a prescriber’s decision. For an online prescription, your weight and height must be verified independently. **Do UK rules require a blood test before Mounjaro is prescribed?** The licence does not: it names no blood test before starting. NICE’s prescribing guide lists blood tests among assessments that depend on clinical circumstances. The pharmacy regulator’s rule is about verification. The prescriber must independently verify your weight and height, and the history behind any qualifying condition. **Do I have to see someone face to face to get a prescription?** No. The GPhC says the type of consultation must be appropriate and give the prescriber enough information to prescribe safely. Its examples include two-way communication with the prescriber, in place of an online questionnaire alone. Your weight, height or BMI must also be verified independently. That can be a video consultation, an in-person check, your clinical records or contact with another healthcare provider such as your GP. **Does Mounjaro affect male fertility?** The licence says the effect of tirzepatide on fertility in humans is unknown. Animal studies did not indicate direct harmful effects on fertility. Our article on Mounjaro and male fertility covers the evidence. Ask your clinician if you are planning a family. HeMed provides clinician-led weight management. Treatment is prescription-only and is prescribed only where a clinician decides it is suitable. This page is general health information, not medical advice. If you are worried about symptoms, speak to your GP, or use NHS 111. Next step: see what the HeMed blood test measures. Sources (23) - Eli Lilly, Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 5.1 and 5.3 (text revised 29 August 2026; emc 8 September 2026). electronic medicines compendium. medicines.org.uk/emc/product/15481/smpc. Accessed 12 November 2026. - General Pharmaceutical Council, “Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet”, February 2025, section 4.2 items d, f, i, j, k and l, pages 20 to 25. assets.pharmacyregulation.org (PDF). Accessed 12 November 2026. - NHS, “Calculate your body mass index (BMI) for adults” (page last reviewed 28 November 2023). nhs.uk/health-assessment-tools. Accessed 12 November 2026. - MHRA, “GLP-1 medicines for weight loss and diabetes: what you need to know”, updated 5 February 2026. gov.uk/government/publications. Accessed 12 November 2026. - NHS, “Type 2 diabetes: symptoms and diagnosis” (page last reviewed 10 February 2025). nhs.uk/conditions/type-2-diabetes/symptoms. Accessed 12 November 2026. - Eli Lilly, Mounjaro KwikPen Patient Information Leaflet, sections 1 and 2 (last revised August 2026; emc 3 September 2026). electronic medicines compendium. medicines.org.uk/emc/product/15481/pil. Accessed 12 November 2026. - MHRA, “MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss”, news story, 8 November 2023. gov.uk/government/news. Accessed 12 November 2026. Announcement wording; the SmPC is the governing text. - NICE, “Tirzepatide for managing overweight and obesity”, technology appraisal guidance TA1026, recommendations 1.1 and 1.2, “Why the committee made these recommendations”, committee discussion section 3.18, implementation section 4.10 and the information for the public, including its “What this means in practice” box (published 23 December 2024, last updated 1 September 2025). nice.org.uk/guidance/ta1026. Accessed 12 November 2026. - NHS England, “Interim commissioning guidance: implementation of NICE TA1026 and the NICE funding variation for tirzepatide (Mounjaro) for the management of obesity”, tables 1 and 2 and the sections on implementation, wrap-around care and reviewing and stopping prescribing (published 2 April 2026). england.nhs.uk. Accessed 12 November 2026. - NICE, “Overweight and obesity management”, NICE guideline NG246, recommendations 1.9.8, 1.9.12, 1.9.16 and 1.9.17 and the definition of non-diabetic hyperglycaemia (published 14 January 2025, last updated 8 January 2026). nice.org.uk/guidance/ng246. Accessed 12 November 2026. - NICE, “Type 2 diabetes: prevention in people at high risk”, public health guideline PH38, recommendation 1.5.7 (published 12 July 2012, last updated 15 September 2017). nice.org.uk/guidance/ph38. Accessed 12 November 2026. - NHS, “High cholesterol” and “Cholesterol levels” (pages last reviewed 13 March 2026). nhs.uk/conditions/high-cholesterol and nhs.uk/conditions/high-cholesterol/cholesterol-levels. Accessed 12 November 2026. - ClinicalTrials.gov, SURMOUNT-1 results record NCT04184622, eligibility criteria and baseline characteristics by sex (results first posted 24 April 2023). clinicaltrials.gov/study/NCT04184622. Accessed 12 November 2026. The percentage of men is derived from the posted counts. - General Pharmaceutical Council, “Providing weight management services: FAQs”, last updated 9 November 2026. pharmacyregulation.org. Accessed 12 November 2026. - NHS, “Overweight and obesity in adults” (page last reviewed 29 April 2026). nhs.uk/conditions/overweight-and-obesity. Accessed 12 November 2026. - NICE, “A guide for prescribing medicines to manage overweight and obesity” and the checklist “Initial assessment before prescribing tirzepatide” (19 March 2025). The guide supports NICE guidance and is not itself guidance. nice.org.uk/guidance/ng246/resources. Accessed 12 November 2026. - NHS, “High blood pressure” (page last reviewed 19 July 2024). nhs.uk/conditions/high-blood-pressure. Accessed 12 November 2026. - Diabetes UK, “Prediabetes” (content last reviewed 27 January 2026). diabetes.org.uk. Accessed 12 November 2026. - NHS, “Tirzepatide”, medicines A to Z (page last reviewed 15 May 2026). nhs.uk/medicines/tirzepatide. Accessed 12 November 2026. - General Pharmaceutical Council, “Weight management medicines and services: a review of GPhC inspections and concerns”, April 2026, pages 2, 3 and 10. assets.pharmacyregulation.org (PDF). Accessed 12 November 2026. - NHS England, “Tirzepatide (Mounjaro) for managing obesity: patient leaflet”, page 2 (first published 20 October 2026). england.nhs.uk/publication. Accessed 12 November 2026. - NHS England, “Weight management injections” (no publication date shown on the page). england.nhs.uk. Accessed 12 November 2026. - General Pharmaceutical Council, “Weight loss medications: FAQ” for patients and the public, last updated 9 November 2026. pharmacyregulation.org. Accessed 12 November 2026. Numbered markers in the page text link to these entries. Statistics describe populations, not any one person’s results. Eligibility thresholds and NHS access rules are quoted from the cited documents as they stood on 12 November 2026, can change, and are not a HeMed assessment of any individual. Published 12 November 2026. --- This is the plain-text version of the article at https://www.hemed.com/blog/mounjaro-eligibility-men-uk, generated from the page on 2026-11-13. It is for information only and is not medical advice. Whether any treatment is right for a person is a clinical decision. Statistics describe populations, not any one person's results.